uperio 50 mg

DB09292. rebozet 50 mg Background Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction It was approved by the FDA after being given the status of priority review for on July 7, 2015